ABBVABBVIE INC. New York Stock Exchange
ABBVIE INC. 1 North Waukegan Road North Chicago IL, 60064-6400 http://www.abbvie.comAbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
- CEO: Richard A. Gonzalez
- Employees: 30,000
- Sector: Healthcare
- Industry: Drug Manufacturers
Latest Stocks Posts
Latest news about the ABBV
- AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by safety and efficacy data from three Phase 3 studies – ADVANCE, MOTIVATE and FORTIFY.View More →
- Is AbbVie a Bad News Buy?
The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.View More →
- Why BeiGene's Shares Jumped on Friday
BeiGene (NASDAQ: BGNE), a Chinese pharmaceutical company, saw its shares rise more than 10% in early trading on Friday. The company has been on a roll lately with its lead oncology drug, Brukinsa (zanubrutinib). On Wednesday, BeiGene said that the Food and Drug Administration had granted accelerated approval to Brukinsa as a therapy for patients with relapsed or refractory marginal zone lymphoma who have already had at least one regimen of an anti-CD20-based antibody treatment.View More →
- AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis
AbbVie Inc (NYSE: ABBV) has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for active ulcerative colitis to FDA and the European Medicines Agency (EMA). Related Content: FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know. The applications cover patients who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. The applications arView More →
- AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely active ulcerative colitis to the U.S. Food and Drug Administration (FDA), and to the European Medicines Agency (EMA) for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response, lost response, or were intolerant to eView More →
- Is AbbVie's 4.9% Dividend Yield Safe?
Drugmaker AbbVie (NYSE: ABBV) pays a relatively high yield of 4.9%. On a $10,000 investment, that's $360 more in annual dividend income you could earn through AbbVie. Multiply that by several years of owning the stock, plus the regular increases the company makes to its payouts, and the difference becomes even more significant.View More →